2024
Progesterone receptor status predicts aggressiveness of human endometriotic lesions in murine avatars
Flores V, Sahin C, Taylor H. Progesterone receptor status predicts aggressiveness of human endometriotic lesions in murine avatars. F&S Science 2024, 6: 65-72. PMID: 39393571, DOI: 10.1016/j.xfss.2024.10.004.Peer-Reviewed Original ResearchProgestin-based therapyAggressive forms of endometriosisPR lesionsProgesterone receptorGnRH antagonistMedroxyprogesterone acetatePR statusEndometriotic lesionsAggressive formResponse to MPAResponse to medical therapyPost-treatment sizeProgesterone receptor statusHuman endometriotic lesionsResponse to progestinsChronic gynecological diseaseDaily subcutaneous injectionsReproductive-age womenMouse xenograft modelResponse to medicationEndometrioma lesionsReceptor statusHormone suppressionPR expressionClinical responseNeuroendocrine Differentiation in Prostate Cancer Requires ASCL1.
Rodarte K, Nir Heyman S, Guo L, Flores L, Savage T, Villarreal J, Deng S, Xu L, Shah R, Oliver T, Johnson J. Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1. Cancer Research 2024, 84: 3522-3537. PMID: 39264686, PMCID: PMC11534540, DOI: 10.1158/0008-5472.can-24-1388.Peer-Reviewed Original ResearchConceptsLoss of RB1Prostate cancerAndrogen receptorEmergence of treatment resistanceGenetically engineered mouse modelsLoss of ASCL1Luminal-like tumorsNeuroendocrine prostate cancerDecreased tumor incidencePoor survival outcomesTranscription factor Ascl1In vivo modelsNE differentiationProstatic adenocarcinomaNeuroendocrine differentiationAllograft tumorsProstate organoidsSurvival outcomesLineage plasticityTreatment resistanceNE featuresTumor incidenceNE lineageProgressive cancerAggressive form
2018
Chapter 7 A Practical Approach to Management of Small Cell Lung Cancer
Talsania A, Chiang A. Chapter 7 A Practical Approach to Management of Small Cell Lung Cancer. 2018, 117-129. DOI: 10.1016/b978-0-323-48565-4.00007-2.Peer-Reviewed Original ResearchSmall cell lung cancerCell lung cancerLung cancerLimited stage small cell lung cancerStage small cell lung cancerSecond-line treatment optionAddition of immunotherapyTime of presentationNCCN guidelinesExtensive diseaseImmunotherapy agentsFrontline treatmentCombination therapyTreatment optionsAggressive formSCLC biologyRB1 lossCancerTherapeutic developmentDiseaseWidespread diseasePossible targetsFunction mutationsContributing factorMolecular determinants
2017
Current and future pharmacologic treatment of nonalcoholic steatohepatitis
Banini BA, Sanyal AJ. Current and future pharmacologic treatment of nonalcoholic steatohepatitis. Current Opinion In Gastroenterology 2017, 33: 134-141. PMID: 28346237, PMCID: PMC5491795, DOI: 10.1097/mog.0000000000000356.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonalcoholic fatty liver diseaseEnd-stage liver diseaseNonalcoholic steatohepatitisLiver diseaseTrend of NAFLDChemokine receptor type 2Future pharmacologic treatmentsCornerstone of therapyStage liver diseaseFatty liver diseasePeroxisome proliferator activator receptorProgression of fibrosisAnti-inflammatory agentsDietary caloric restrictionGlucagon-like peptide 1 pathwayReceptor type 2Liver histologyMetabolic endotoxemiaPharmacologic treatmentTherapeutic optionsHepatocellular cancerAntifibrotic agentsIntestinal microbiomeAggressive formPharmacologic targetChapter 7 MicroRNAs in Idiopathic Pulmonary Fibrosis Partners in Health and Disease
Pandit K, Kaminski N. Chapter 7 MicroRNAs in Idiopathic Pulmonary Fibrosis Partners in Health and Disease. 2017, 179-202. DOI: 10.1016/b978-0-12-800553-8.00007-x.Peer-Reviewed Original ResearchIdiopathic pulmonary fibrosisEtiology of IPFInterstitial lung diseaseExtent of fibrosisIPF patientsPulmonary fibrosisIrreversible scarringLung diseaseTreatment optionsAggressive formPotent cytokineGrowth factorDiseaseDreadful diseaseFibrosisLungTGFCurrent knowledgeMicroRNAsTarget genesGas exchangePatientsCytokinesScarringEtiology
2016
Metabolic Signature on 18F-FDG PET/CT, HER2 Status, and Survival in Gastric Adenocarcinomas
Celli R, Colunga M, Patel N, Djekidel M, Jain D. Metabolic Signature on 18F-FDG PET/CT, HER2 Status, and Survival in Gastric Adenocarcinomas. Journal Of Nuclear Medicine Technology 2016, 44: 234-238. PMID: 27789750, DOI: 10.2967/jnmt.116.181479.Peer-Reviewed Original ResearchConceptsGastroesophageal junction adenocarcinomaHER2 statusPET/CTHER2 casesF-FDG PET/CTHuman epidermal growth factor 2Metabolic signaturesEpidermal growth factor 2Lymph node metastasisWorse overall survivalHER2-negative casesHistologic signatureOverall survivalGrowth factor 2Junction adenocarcinomaNode metastasisPreoperative parametersTumor histologyGastric adenocarcinomaHER2 overexpressionHigh SUVMedian SUVPathology reportsTumor SUVAggressive formSYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression
Black J, Menderes G, Bellone S, Schwab CL, Bonazzoli E, Ferrari F, Predolini F, De Haydu C, Cocco E, Buza N, Hui P, Wong S, Lopez S, Ratner E, Silasi DA, Azodi M, Litkouhi B, Schwartz PE, Goedings P, Beusker PH, van der Lee MM, Timmers CM, Dokter WH, Santin AD. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression. Molecular Cancer Therapeutics 2016, 15: 1900-1909. PMID: 27256376, DOI: 10.1158/1535-7163.mct-16-0163.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnimalsAntibody-Dependent Cell CytotoxicityAntineoplastic AgentsBystander EffectCathepsin BCell Line, TumorCell SurvivalClass I Phosphatidylinositol 3-KinasesCystadenocarcinoma, SerousDisease Models, AnimalDuocarmycinsFemaleGene ExpressionHumansImmunoconjugatesIndolesMiceMiddle AgedMutationPhosphatidylinositol 3-KinasesPyrrolidinonesReceptor, ErbB-2Survival AnalysisUterine NeoplasmsXenograft Model Antitumor AssaysConceptsUterine serous carcinomaAntibody-dependent cellular cytotoxicityHER2/neu expressionAntibody-drug conjugatesT-DM1Neu expressionHER2-targeting antibody-drug conjugateNovel antibody-drug conjugateNovel HER2-targeting antibody-drug conjugatePrimary USC cell linesHigh HER2 expressionHER2/neu oncogeneHER2/neuMouse xenograft modelUSC cell linesFlow cytometry assayEndometrial cancerSerous carcinomaHER2 expressionTrastuzumab emtansineClinical studiesCellular cytotoxicitySYD985Aggressive formExpress HER2Clinical course and prognosis in patients with Gaucher disease and parkinsonism
Lopez G, Kim J, Wiggs E, Cintron D, Groden C, Tayebi N, Mistry PK, Pastores GM, Zimran A, Goker-Alpan O, Sidransky E. Clinical course and prognosis in patients with Gaucher disease and parkinsonism. Neurology Genetics 2016, 2: &na;. PMID: 27123476, PMCID: PMC4830189, DOI: 10.1212/nxg.0000000000000057.Peer-Reviewed Original ResearchClinical courseGaucher diseaseParkinson's diseaseOnset of parkinsonismRetrospective observational studyIdiopathic Parkinson's diseaseReliable prognostic indicatorMild cognitive dysfunctionLevodopa responseParkinsonian symptomsLewy bodiesOlfactory testingPrognostic indicatorClinical centersCognitive dysfunctionClinical dataFamily historyObservational studyGBA1 mutationsAggressive formParkinsonian phenotypeNeurocognitive evaluationParkinsonismPatientsSlow course
2015
An update on the current pharmacotherapy for endometrial cancer
de Haydu C, Black JD, Schwab CL, English DP, Santin AD. An update on the current pharmacotherapy for endometrial cancer. Expert Opinion On Pharmacotherapy 2015, 17: 489-499. PMID: 26629895, DOI: 10.1517/14656566.2016.1127351.Peer-Reviewed Original ResearchConceptsEndometrial cancerMainstay of treatmentCommon gynecologic malignancyCurrent conventional therapiesGynecologic malignanciesCurrent pharmacotherapyAvailable pharmacotherapiesConventional therapyCurrent therapiesEndometrial tumorsTargeted therapyImmunohistochemical characterizationRadiation therapyClinical careAggressive formNew therapiesPreclinical settingTherapyTherapeutic agentsCancerPharmacotherapyTumorsAvailable literatureHistoric treatmentTreatmentOsteonecrosis of the Jaw in Association With Chemotherapy in the Setting of Cutaneous T-Cell Lymphoma
DeSesa CR, Appugounder S, Haberland C, Johnson MP. Osteonecrosis of the Jaw in Association With Chemotherapy in the Setting of Cutaneous T-Cell Lymphoma. Journal Of Oral And Maxillofacial Surgery 2015, 74: 292-301. PMID: 26296596, DOI: 10.1016/j.joms.2015.07.019.Peer-Reviewed Original ResearchConceptsT-cell lymphomaCutaneous T-cell lymphomaSézary syndromeMycosis fungoidesIntraoral manifestationsCases of osteonecrosisNon-Hodgkin lymphomaLate-stage variantsDiffuse erythrodermaMultifocal osteonecrosisOral manifestationsOverall prognosisCutaneous ulcersErythematous lesionsCase reportCommon subtypePrevalent subtypeAggressive formCutaneous edemaSyndromeFungoidesOsteonecrosisPatientsLymphomaCommon formSomatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis
Erson-Omay EZ, Çağlayan AO, Schultz N, Weinhold N, Omay SB, Özduman K, Köksal Y, Li J, Serin Harmancı A, Clark V, Carrión-Grant G, Baranoski J, Çağlar C, Barak T, Coşkun S, Baran B, Köse D, Sun J, Bakırcıoğlu M, Moliterno Günel J, Pamir MN, Mishra-Gorur K, Bilguvar K, Yasuno K, Vortmeyer A, Huttner AJ, Sander C, Günel M. Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis. Neuro-Oncology 2015, 17: 1356-1364. PMID: 25740784, PMCID: PMC4578578, DOI: 10.1093/neuonc/nov027.Peer-Reviewed Original ResearchConceptsHigh-grade gliomasSomatic POLE mutationsPOLE mutationsMalignant high-grade gliomasLonger progression-free survivalProgression-free survivalSomatic mutationsOverall survivalPediatric patientsBetter prognosisClinical featuresImproved prognosisClinical behaviorImmune cellsBizarre cellsAggressive formGlioblastoma multiformeDisease pathophysiologyMolecular subgroupsHomozygous germline mutationGermline mutationsPrognosisGlioma subtypesComprehensive genomic analysisDistinct subgroups
2014
Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo
Schwab CL, Bellone S, English DP, Roque DM, Lopez S, Cocco E, Nicoletti R, Bortolomai I, Bonazzoli E, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. British Journal Of Cancer 2014, 111: 1750-1756. PMID: 25268372, PMCID: PMC4453741, DOI: 10.1038/bjc.2014.519.Peer-Reviewed Original ResearchMeSH KeywordsAdultAfatinibAgedAged, 80 and overAnimalsApoptosisCell CycleCell ProliferationCystadenocarcinoma, SerousEndometrial NeoplasmsFemaleHumansImmunoenzyme TechniquesIn Situ Hybridization, FluorescenceIn Vitro TechniquesMiceMice, SCIDMiddle AgedPhosphorylationQuinazolinesReceptor, ErbB-2Signal TransductionTumor Cells, CulturedUterine NeoplasmsXenograft Model Antitumor AssaysConceptsUterine serous carcinomaUSC cell linesHER2/neu gene amplificationNeu gene amplificationAfatinib exposureOverall survivalCell linesHER2/neu amplificationEfficacy of afatinibPrimary USC cell linesGrowth of HER2Treatment of HER2Serous endometrial cancerErbB tyrosine kinase inhibitorsHER2/neuTyrosine kinase inhibitorsGene amplificationFlow cytometry assayCell cycle distributionUSC xenograftsEndometrial cancerSerous carcinomaUterine cancerAggressive formTumor xenografts
2011
Gestational Choriocarcinoma
Hui P. Gestational Choriocarcinoma. Current Clinical Pathology 2011, 127-137. DOI: 10.1007/978-1-61779-394-3_8.Peer-Reviewed Original ResearchGestational choriocarcinomaMalignant tumorsMethotrexate-based chemotherapyMortality of patientsDecidua of pregnancyHematogenous spreadCure rateFatal malignancyTrophoblastic diseaseChemotherapy managementAggressive formChoriocarcinomaChorial villiTumorsTumor cellsSarcomaDiseaseChemotherapyPatientsPregnancyDramatic decreaseMalignancyMortalityPlacentaDeciduaChronic lymphocytic leukemia: prognostic factors and impact on treatment.
Parker TL, Strout MP. Chronic lymphocytic leukemia: prognostic factors and impact on treatment. Discovery Medicine 2011, 11: 115-23. PMID: 21356166.Peer-Reviewed Original ResearchConceptsChronic lymphocytic leukemiaPrognostic markerBiology of CLLClinical staging systemStandard chemotherapy regimensObvious survival advantageSymptomatic leukemiaChemotherapy regimensMature B cellsPrognostic factorsProlong survivalIndolent diseaseStaging systemClinical managementImmediate treatmentDisease progressionEarly treatmentLymphocytic leukemiaSurvival advantageAggressive formB cellsClinical heterogeneityClonal malignancyEarly interventionPatients
2009
Soluble IL-2RA Levels in Multiple Sclerosis Subjects and the Effect of Soluble IL-2RA on Immune Responses
Maier LM, Anderson DE, Severson CA, Baecher-Allan C, Healy B, Liu DV, Wittrup KD, De Jager PL, Hafler DA. Soluble IL-2RA Levels in Multiple Sclerosis Subjects and the Effect of Soluble IL-2RA on Immune Responses. The Journal Of Immunology 2009, 182: 1541-1547. PMID: 19155502, PMCID: PMC3992946, DOI: 10.4049/jimmunol.182.3.1541.Peer-Reviewed Original ResearchConceptsMultiple sclerosisIL-2 receptorMS subjectsHealthy controlsOrgan-specific autoimmune disordersChronic systemic inflammationType 1 diabetesT cell proliferationMultiple sclerosis subjectsStrong genetic factorIL-2 signalingSIL-2RaSystemic inflammationAutoimmune disordersImmunological perturbationsAutoimmune diseasesIL-2RAControl subjectsMS casesSerum concentrationsDisease onsetSpecific allelic variantsImmune responseAggressive formDisease risk
2004
Hepatoblastoma in low birth weight infants: an institutional review
Kapfer SA, Petruzzi MJ, Caty MG. Hepatoblastoma in low birth weight infants: an institutional review. Pediatric Surgery International 2004, 20: 753-756. PMID: 15538588, DOI: 10.1007/s00383-004-1292-6.Peer-Reviewed Original ResearchConceptsLow birth weight infantsBirth weight infantsWeight infantsBirth weightLow birth weightOxygen free radicalsRecurrent diseaseVentilatory supportStandard carePulmonary diseaseSupplemental oxygenPatient survivalAggressive formInstitutional reviewSubset of hepatoblastomasHepatoblastomaPatientsDiseaseInfantsFree radicalsReviewEtiologyCare
2000
Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer
Yu H, Bharaj B, Vassilikos E, Giai M, Diamandis E. Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer. Breast Cancer Research And Treatment 2000, 59: 153-161. PMID: 10817350, DOI: 10.1023/a:1006356502820.Peer-Reviewed Original ResearchConceptsBreast cancerAndrogen receptorAggressive formCAG repeatsPositive lymph nodesPrimary breast cancerRisk of deathAR transcriptional activityImpact of androgensPatients' overall survivalAction of androgensBreast cancer tissuesBreast cancer progressionAndrogen receptor geneLength of CAGLong CAG repeatsOverall survivalLymph nodesPathological variablesPatient survivalHistological gradeHomozygous womenProstate cancerMean CAGDisease features
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply